首页|布地格福联合乙酰半胱氨酸颗粒对慢性阻塞性肺疾病急性加重期患者肺功能、免疫指标的影响

布地格福联合乙酰半胱氨酸颗粒对慢性阻塞性肺疾病急性加重期患者肺功能、免疫指标的影响

扫码查看
原文链接
  • 万方数据
  • 维普
目的 探讨布地格福吸入气雾剂联合乙酰半胱氨酸颗粒对慢性阻塞性肺疾病急性加重期(AECOPD)患者肺功能、免疫指标的影响。方法 选择 2022 年3 月～2023 年12 月于阜南县人民医院诊治的AECOPD患者106 例，根据随机数表法分为对照组(n=53)和联合组(n=53)。两组患者均行常规对症治疗，对照组在此基础上使用布地格福气雾剂吸入治疗，联合组在对照组的基础上联合乙酰半胱氨酸颗粒剂治疗。比较两组患者的肺功能、免疫指标、炎症因子、临床疗效及不良反应发生率。结果 治疗后，联合组患者的总有效率为 94。34%(50∕53)，高于对照组患者的 81。13%(43∕53)，差异有统计学意义(χ2=4。296，P<0。05)。治疗后，联合组患者的FVC、FEV1、FEV1∕FVC分别为(1。84±0。16)L、(1。25±0。14)L、(62。15±5。02)%，均高于对照组患者的(1。65±0。18)L、(0。97±0。12)L、(54。05±4。77)%，差异均有统计学意义(P<0。05)。治疗后，联合组患者的 CD4+、CD4+∕CD8+分别为(35。41±3。21)%、(1。26±0。21)%，均高于对照组患者的(33。62±3。26)%、(1。07±0。24)%;CD8+为(30。43±3。21)%，低于对照组患者的(33。45±3。46)%，差异均有统计学意义(P<0。05)。治疗后，联合组患者的IL-6、IL-8、TNF-β水平分别为(8。31±1。23)、(310。12±11。21)、(42。14±6。21)，均低于对照组患者的(10。46±1。43)、(347。52±11。24)、(56。02±7。03)，差异均有统计学意义(t=8。540、17。628、11。084，P<0。05)。对照组患者的不良反应总发生率为16。98%(9∕53)，与联合组患者的7。55%(4∕53)比较，差异无统计学意义(P>0。05)。结论 布地格福吸入气雾剂联合乙酰半胱氨酸颗粒治疗可改善AECOPD患者的肺功能和免疫指标，在减轻炎症反应、改善临床症状方面效果显著，值得临床应用。
Influence of budesonide∕formoterol fumarate dihydrate and acetylcysteine granules on pulmonary function and immune indices in patients with acute exacerbation of chronic obstructive pulmonary disease
Objective explore the impact of budesonide∕formoterol fumarate dihydrate inhalation combined with acetylcysteine granules on pulmonary function and immune indices in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A cohort of 106 AECOPD patients treated at Funan County People's Hospital from March 2022 to December 2023 was selected and randomized into a control group(n=53)and a combination therapy group(n=53).Both groups received conventional symptomatic treatment;the control group was treated with budesonide∕formoterol fumarate dihydrate inhalation,while the combination group received acetylcysteine granules in addition to the conventional treatment.Lung function,immune indices,inflammatory factors,clinical efficacy,and the incidence of adverse reactions were compared between the two groups.Results Post-treatment,the combination group demonstrated higher forced vital capacity(FVC),forced expiratory volume in one second(FEV1),and FEV1∕FVC ratios compared to the control group(P<0.05).Immune indices post-treatment,including CD4+and CD4+∕CD8+ratios,were higher in the combination group than in the control group(P<0.05),while CD8+levels were lower(P<0.05).Levels of IL-6,IL-8,and TNF-β were reduced in the combination group compared to the control group(P<0.05).The total effective rate was significantly higher in the combination group(94.34%,50∕53)than in the control group(81.13%,43∕53)(χ2=4.296,P<0.05).The incidence of adverse reactions did not differ significantly between the two groups(P>0.05).Conclusion The combination therapy of budesonide∕formoterol fumarate dihydrate inhalation and acetylcysteine granules can improve pulmonary function and immune indices in AECOPD patients,with significant effects on reducing inflammation and improving clinical symptoms,suggesting its potential for broad application.

Budesonide∕Formoterol fumarate dihydrate inhalation aerosolAcetylcysteineChronic obstructive pulmonary disease,acute exacerbationPulmonary functionImmune indices

乔龙军、王义、戎玉东、王彪

展开 >

236300 阜阳,阜南县人民医院呼吸与危重症医学科

阜阳市第二人民医院肿瘤内科

布地格福吸入气雾剂 乙酰半胱氨酸 慢性阻塞性肺疾急性加重期 肺功能 免疫指标

安徽省高等学校科学研究项目

2022AH051191

2024

10.3969∕j.issn.1674-3245.2024.05.021

中华保健医学杂志
中国人民解放军总后勤部卫生部保健局

中华保健医学杂志

CSTPCD
影响因子：0.477
ISSN：1674-3245
年,卷(期)：2024.26(5)